Protein / target
Immunoglobulin heavy constant epsilon
Protein at a glance
Biological role
Immunoglobulin receptor binding
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Constant region of immunoglobulin heavy chains.
View complete UniProt function annotationHide complete annotation
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)
Subcellular location
Domains and Gene Ontology detail (31)Hide
Domains & features
Gene Ontology
- Cextracellular region
- Cextracellular space
- CIgE B cell receptor complex
- Cimmunoglobulin complex, circulating
- Cplasma membrane
- Fantigen binding
- Fimmunoglobulin receptor binding
- Padaptive immune memory response
- Padaptive immune response
- Pantibacterial humoral response
- Pantibody-dependent cellular cytotoxicity
- PB cell activation
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodie…
- ·IgE B cell receptor complex
- ·antigen binding
- ·adaptive immune response
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Ig epsilon chain C region inhibitor
Indicated for Asthma, Lung Diseases, Obstructive, Rhinitis, Urticaria
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- CHMP positive opinion
CHMP positive opinion: Adcomfo (EMA)
- Label change
Label change: OMALIZUMAB (BLA103976)
- Regulatory approval
Approval: Omlyclo (EMA)
- New publicationOmalizumab for the Treatment of Multiple Food Allergies.
- Indication expanded
Indication expansion: OMALIZUMAB (BLA103976)
- Supplemental approval
Supplemental approval: OMALIZUMAB (BLA103976)
- Label change
Label change: OMALIZUMAB (BLA103976)
- New publicationOmalizumab for treatment of idiopathic angioedema.
- New publicationPhase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
- Supplemental approval
Supplemental approval: OMALIZUMAB (BLA103976)
- Safety communication
Drug Safety Update: Omalizumab: potential risk of arterial thrombotic events
- New publicationRandomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.